摘要
目的探讨干扰素α-2b（IFNα-2b）联合病毒唑治疗慢性丙型病毒性肝炎（CHC）的疗效。方法122CHC随机分为2组：A组IFNα-2b联合利巴韦林，B组IFNα-2b。疗程24wk，治疗结束后随访24wk。结果A组的终末病毒学应答（ETVR）率、持续病毒学应答（SVR）率、终末生化应答率、持续生化应答率分别为75．8％、58．1％、83．9％、74．2％，B组分别为31．7％、13．3％、36、7％、16．7％。A组与B组ETVR率、SVR率、终末生化应答率、持续生化应答率经χ^2检验，P值均小于0．01，两组间差异有非常显著性。结论IFNα-2b联合利巴韦林治疗CHC明显优于单独使用IFNα-2b。
Objective To Study the cffieacy of interferon α - 2b （ IFNα - 2b） combined with ribavirin in the treatment of chronic hepatitis C. Methods 122 patients with chronic hepatitis C were randomly divided into two groups （A, B ）. 62 patients in group A were treated with IFNα - 2b and ribavirin. 60 patients in group B were treated with IFNα - 2b. All patients were treated for 24 - weeks and 24 - weeks fellow up. Results The percentages of patients with the end of treatment vius response（ETVR）. The sustained virological response （SVR） the end of alanine amimotransferase （ALT） response. The sustatained ALT response in group A were significantly higher than those in group B （75.8% ,58. 1% ,83.9% ,74.2% vs 31.7% ,13.3% ,35.7% ,16.7% ）. The percentages of response rate were superior between the two groups （P 〈 0. 01 ）. Conclusion IFNα -2b combined with ribavirin is more of effective for trcaiting patients with chronic hepatitis C than IFNα -2b does.
